Thursday, January 26, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

Rare and Emerging Viral Disease Impact on Special Populations

by Global Biodefense Staff
December 1, 2014
Impact of Viruses on Special Populations

Credit: Shutterstock

The National Institute of Allergy and Infectious Diseases (NIAID) has a requirement for the development of therapeutic strategies for select rare and emerging viral diseases in special populations.

The effort will be supported by a Broad Agency Announcement (BAA) officially released Dec. 15, 2014.

A rare (or orphan) disease is generally considered to have a prevalence of fewer than 200,000 affected individuals in the United States. Emerging viral diseases can be defined as infections that have newly appeared in a population, or have existed but are rapidly increasing in incidence in that population or geographic range.

The study of serious rare or emerging viral infections in these populations provides unique and special challenges and treatment options are frequently sparse. Consequently, the development of effective therapies or therapeutic strategies for rare viral diseases or viral diseases in special populations remains a significant unmet medical need.

Natural history studies that focus on understanding the range of manifestations, disease progression, disease presentation in various populations and the establishment of biomarkers of clinical progression and correlates of clinical outcome are being recognized as critical to facilitate effective product development programs and overcome issues that have led to stalled or failed product development strategies.

For the purposes of the forthcoming BAA, the targeted patient populations are those for which there is a significant unmet medical need for therapeutic options for rare/emerging viral diseases that are not being addressed by the pharmaceutical industry or other significant clinical initiatives, including: children (neonates through adolescents); the elderly, transplant recipients, and pregnant women.

The following are some examples of viral diseases of interest which pose an increased risk to special populations:

  • Congenital Cytomegalovirus (CMV)
  • Serious Enteroviral Diseases
  • Epstein-Barr Virus (EBV)
  • Neonatal Herpes Virus
  • Flavivirus
  • Filovirus
  • Human Herpesvirus-6 (HHV-6)
  • Adenovirus
  • Norovirus
  • Viral Encephalitis
  • Lassa Fever Virus
  • Chikungunya

Eligible clinical studies under the BAA include:

  • Interventional trials of safety and effectiveness for treatments
  • Natural history studies of the target viral diseases to assist in the design trial endpoints
  • Validation of biomarkers or surrogate markers of clinical responses and safety
  • Validation of diagnostic tests for predicting clinical response to therapy
  • Proof of principle studies to further product development
  • Exposure/exposure-response studies to optimize therapies
  • Assessment of the emergence of resistance to antiviral therapies
  • Analysis of existing databases or patient charts

Contracts awarded under this mechanism will not support surveillance or transmission studies. Further details are available under Solicitation Number: BAA-NIAID-DMID-NIH-AI-2014028.

Tags: AdenovirusAntimicrobialsAntiviralsBAABiomarkersChikungunyaEmerging ThreatsLassa FeverNIAIDNorovirus

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC